Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label.
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2
Meet LPB's 7 Young Heroes for 2024 | Entertainment/Life theadvocate.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theadvocate.com Daily Mail and Mail on Sunday newspapers.
The Larry H. and Gail Miller Family Campus of Primary Children s Hospital in Lehi was dedicated in a ceremony on Friday, and will open for patients on Feb. 12.